New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
07:26 EDTSNE, ILMNSony, Illumina announce genome information platform joint venture
Sony Corporation (SNE) announced that Sony, M3, Inc. and Illumina (ILMN) have agreed to form a collaboration to launch a "genome information platform" in Japan. Sony and M3 will establish a new company with Illumina as a minority investor, by the end of February. The new company's "genome information platform" business will provide a genome analysis service for research institutions and enterprises in Japan. It will also aggregate genome data with related information such as medical data to support research in areas where genome data is applied. Going forward, the scope of its business is expected to extend beyond medical research, to provide a service platform that supports the use of genetic data and medical information for personalized medicine and healthcare services for individual patients.
News For SNE;ILMN From The Last 14 Days
Check below for free stories on SNE;ILMN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 29, 2014
10:00 EDTSNESony volatility at low end of historic range as shares advance
Subscribe for More Information
07:46 EDTSNESony, Samsung to launch smartphones with metal-alloy bodies, DigiTimes says
Subscribe for More Information
06:19 EDTSNESprint to carry Sony's next Xperia phone in the U.S., WSJ reports
Subscribe for More Information
August 28, 2014
12:30 EDTSNENetflix buys flagship series 'The Blacklist' for $2M per episode, Deadline says
Subscribe for More Information
August 26, 2014
09:01 EDTSNEElectronic Arts launches Madden NFL 15 on Xbox One, PS4
Subscribe for More Information
August 25, 2014
06:44 EDTSNESony's PSN back online following cyber attack
Subscribe for More Information
06:04 EDTSNEAmerican Airlines flight diverted as Sony exec receives threat, Re/code reports
Subscribe for More Information
August 24, 2014
16:34 EDTSNESony says PlayStation impacted by Denial of Service attack
Subscribe for More Information
August 22, 2014
11:59 EDTSNEGameStop surges after Q2 EPS, revenue beat expectations
Subscribe for More Information
August 21, 2014
05:42 EDTILMNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
10:04 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:18 EDTILMNIllumina upgraded to Outperform from Neutral at Wedbush
Subscribe for More Information
August 19, 2014
11:32 EDTILMNLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use